ASBPW Latest News, Press Relases and Analysis

All

Press Releases

21 hours ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

7 days ago - By: ACCESS Newswire - Mentions: ASBP

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

a month ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

2 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc. Announces CEO Transition

8 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

8 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

2 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

2 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

3 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

3 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

3 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

9 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

9 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

4 months ago - By: Yahoo Finance - Mentions: ASBP VZ MA

Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback

4 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

5 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

5 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

6 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

6 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

7 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

7 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

7 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

8 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

9 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

9 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

10 months ago - By: ACCESS Newswire - Mentions: ASBP

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

10 months ago - By: ACCESS Newswire - Mentions: PWUP ASBP

ASPIRE BIOPHARMA HOLDIN-CW27 (ASBPW) Stock News

ASBPW Latest News, Press Relases and Analysis

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq